Acute Lymphoblastic Leukemia ALL: Clinical Trials

5 trials for Acute Lymphoblastic Leukemia ALL, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 2 completed. 5 Phase 2, 2 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Recruiting 3, Completed 2
Phase 12Completed 2
Phase 32Recruiting 2

Follow Acute Lymphoblastic Leukemia ALL: new trials by email Literature Review of Acute Lymphoblastic Leukemia ALL trials Research Report on Acute Lymphoblastic Leukemia ALL

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Blinatumomab, Reinduction-2 omission, Chemo-light Maintenance 2 - Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic
Phase 2 / Phase 3RecruitingInstitute of Hematology & Blood Diseases Hospital, China30002025-03-032025-08-26
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Blinatumomab (Group A), Venetoclax (nonRand Group), Blinatumomab (Group B) - Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic
Phase 2 / Phase 3RecruitingInstitute of Hematology & Blood Diseases Hospital, China18002025-01-032026-07-23
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders
Hem101 - Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL
Phase 1 / Phase 2CompletedNational Research Center for Hematology, Russia582024-11-262026-02-09
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
Autologous hematopoietic stem cell transplantation combined with CD19-CART - Acute Lymphoblastic Leukemia ALL
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China202024-06-252024-09-23
Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation
HSCT donor leukemia-specific cytotoxic T-cells - Acute Lymphoblastic Leukemia ALL, Acute Myeloid Leukemia (AML)
Phase 1 / Phase 2CompletedFondazione IRCCS Policlinico San Matteo di Pavia152021-02-132025-03-07

Narrower conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma (5)  ·  Burkitt Lymphoma (2)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)

Broader conditions

Hematologic Diseases (5)  ·  Hemic and Lymphatic Diseases (5)  ·  Immune System Diseases (5)  ·  Immunoproliferative Disorders (5)  ·  Leukemia (5)  ·  Leukemia, Lymphoid (5)  ·  Lymphatic Diseases (5)  ·  Lymphoproliferative Disorders (5)  ·  Neoplasms (5)  ·  Neoplasms by Histologic Type (5)  ·  Lymphoma (3)  ·  DNA Virus Infections (2)  ·  Epstein-Barr Virus Infections (2)  ·  Herpesviridae Infections (2)  ·  Infections (2)

Interventions

Dexamethasone (2)  ·  Methotrexate (2)  ·  Vincristine (2)  ·  blinatumomab (2)  ·  Asparaginase (1)  ·  Cyclophosphamide (1)  ·  Cytarabine (1)  ·  Daunorubicin (1)  ·  Prednisone (1)  ·  venetoclax (1)

Sponsors

Institute of Hematology & Blood Diseases Hospital, China (3)  ·  Fondazione IRCCS Policlinico San Matteo di Pavia (1)  ·  National Research Center for Hematology, Russia (1)

Countries

China (3)  ·  Hong Kong (2)  ·  Italy (1)  ·  Russia (1)

Top investigators

Xiaofan Zhu, MD (2)

Results publications

PMID 37141547, PMID 40547030